

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	10271-021-999	09/724,531
	APPLICANT Young et al.	
	FILING DATE November 28, 2000	GROUP 1641

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SBC	DU	6,537,809	3/25/03	Brams	—	—	
	DV	6,096,551	8/1/00	Barbas et al.	—	—	
	DW	5,693,762	12/2/97	Queen et al.	—	—	
	DX	5,585,089	12/17/96	Queen et al.	—	—	
✓	DL	5,939,068	8/17/99	Brams et al.	—	—	

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
SBC	DY	WO 00/29584	5/25/00	PCT	—	—	
SBC	DM	WO 96/05229	2/22/96	PCT	—	—	

### OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

SBC	DZ	Anderson et al., 1985, "Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay," J. Clin. Microbiol. 22:1050-1052
	EA	Boulianne et al., 1984, "Production of functional chimaeric mouse/human antibody," Nature 312(5995):643-646
	EB	Carson et al., 1986, "Human lymphocyte hybridomas and monoclonal antibodies," Adv. Immunol. 38:275-311
	EC	Conrad et al., 1987, "Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic," Pediatr. Infect. Dis. J. 6(2):152-158
	ED	Cruse et al., 1995, Illustrated Dictionary of Immunology, Boca Raton: CRC Press, pp. 18-19
	EE	Dorland's Illustrated Medical Dictionary, 1994, 28 <sup>th</sup> ed., Philadelphia: WB Saunders p. 874
	EF	Duenas et al., 1996, "In vitro immunization of naïve human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display," Immunology 89:1-7
	EG	Duenas et al., 1996, "Selection of phage displayed antibodies based on kinetic constants," Molecular Immunol. 33(3):279-285
	EH	Everitt et al., 1996, "The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers," J. Infect. Dis. 174:463-469
	EI	Foote et al., 1995, "Kinetic and affinity limits on antibodies produced during immune response," Proc. Nat'l Acad. Science USA 92:1254-1256
	EJ	Foote et al., 1991, "Kinetic maturation of an immune response," Nature 352:530-532
	EK	Glaser et al., 1992, "Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," J. Immunol. 149:3903-3913
	EL	Greenspan et al., 1999, "Defining epitopes: It's not as easy as it seems," Nature Biotechnology 17:936-937
	EM	Groves et al., 1987, "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion," Hybridoma 6(1):71-76
	EN	Hall et al., 1985, "Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease," JAMA 254(21):3047-3051
	EO	Hall et al., 1983, "Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study," N. Engl. J. Med. 308(24):1443-1447
	EP	Hall et al., 1975, "Nosocomial respiratory syncytial virus infections," N. Engl. J. Med. 293(26):1343-1346
✓	EQ	Haynes et al., 2002, "Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection," J. Virol. 76(14):6873-6881

APR 21 2004  
 SBC  
 PATENT & TRADEMARK OFFICE

ER	Johnson et al., 1999, "A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19," J. Infect. Dis. 180(1):35-40
ES	Karlsson et al., 1997, "Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors," J Immunol. Meth. 200:121-133
ET	Knappik et al., 2000, "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides," J. Mol. Biol. 296:57-86
EU	Liu et al., 1987, "Expression of mouse:human immunoglobulin heavy-chain cDNA in lymphoid cells," Gene 54(1):33-40
EV	LoBuglio et al., 1989, "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response," Proc. Natl. Acad. Sci. USA 86(11):4220-4224
EW	Morrison et al., 1985, "Transfectomas provide novel chimeric antibodies," Science 229(4719):1202-1207
EX	Morrison et al., 1984, "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA 81(21):6851-6855
EY	Myszka et al., 1999, "Survey of the 1998 optical biosensor literature," J. Mol. Recog. 12:390-408
EZ	Newman et al., 1992, "'Primitization' of recombinant antibodies for immunotherapy of human diseases: A Macaque/Huab chimeric antibody against human CD4," Biotechnol. 10:1455-1460
FA	Prince et al., 1996, "Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid," J. Infect. Dis. 173:598-608
FB	Raman et al., 1992, "Diffusion-limited rates for monoclonal antibody binding to cytochrome," Biochem. 31:10370-10379
FC	Roost et al., 1995, "Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity," PNAS USA 92:1257-1261
FD	Rosok et al., 1995, "A combinatorial library strategy for the rapid humanization of anticarcinoma BR 96 Fab," JBC 271(27):22611-22618
FE	Rudikoff et al., 1982, "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA 79(6):1979-1983
FF	Sahagan et al., 1986, "A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen," J. Immunol. 137(3):1066-1074
FG	Schier et al., 1996, "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," J. Mol. Biol. 263(4):551-567
FH	Stemplewski et al., 1988, "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," Proc. Natl. Acad. Sci. USA 85(13):4852-4856
FI	Sun et al., 1987, "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A," Proc. Natl. Acad. Sci. USA 84(1):214-218
FJ	Takeda et al., 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314(6010):452-454
FK	Talwar et al., 1976, "Isoimmunization against human chorionic gonadotropin with conjugates of processed beta-subunit of the hormone and tetanus toxoid," Proc. Natl. Acad. Sci. USA 73(1):218-222
FL	van Wyke et al., 1985, "Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus," Virology 143(2):569-582
FM	Wald et al., 1988, "In re ribavirin: a case of premature adjudication?" J. Pediatr. 112(1):154-158
FN	Wright et al., 1982, "Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children," Infect. Immun. 37(1):397-400
FO	Wu et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an avb-specific humanized mAb," PNAS 95:6037-6042
FP	Geneseq Database, Accession no: AAW70933, entry date Oct. 1998 from patent no FR2758331-A1 of Bourgeois et al.
DN	Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24
DO	Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45
DP	Landry et al., "Evaluation of reconstituted lyophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Infect. Dis. 166A: 969
DQ	Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non-HIV virology, Intersci. Conf. Antimicrob. Agents Chemother. Toronto
DR	Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session infect. dis. 130A:768
DS	Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976
DT	Sorbera et al., 1998, "Palivizumab," Drug Data Report 20:702-703

EXAMINER

Hany B. Chen

DATE CONSIDERED

May 21, 2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.